BioSpace News Archive

Biotech Beam Therapeutics has dosed the first patient in a Phase I/II study of its base-edited CAR-T therapy in relapsed or refractory T-cell acute lymphoblastic leukemia/T-cell lymphoblastic lymphoma.

Citing the need to improve its Risk Evaluation and Mitigation Strategy, the regulator has declined AstraZeneca’s bid to get its C5 complement inhibitor approved in neuromyelitis optica spectrum disorder.

Monitoring rebates from drugmakers will be critical as provisions of the Inflation Reduction Act are implemented, including drug price negotiations, the Government Accountability Office contends.

The vaccine maker reported new trial data confirming an 8.7 to 11-fold increase in neutralizing antibodies against circulating strains, including the highly watched BA.2.86, EG.5 and FL.1.5.1 variants.

Interim data from the company’s late-stage clinical trial suggests its cell therapy treatment for heart failure likely won’t meet the primary efficacy endpoint, BioCardia announced on Tuesday.

Led by new investor Google Ventures, it is one of 2023’s larger fundraising efforts and comes less than a year after a $4 billion deal with Takeda for a Nimbus autoimmune disease treatment.

Motus GI Holdings, Inc., a medical technology company focused on improving endoscopic outcomes and experiences, announced the appointment of Scott Durbin to the Company’s Board of Directors.

Moderna, Inc. (Nasdaq:MRNA), today announced its participation in a fireside chat at Morgan Stanley’s 21st Annual Global Healthcare Conference on Tuesday, September 12th at 12:15 p.m. ET.

Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that it has disclosed certain historical and pro forma financial information with respect to its proposed acquisition of XIIDRA (lifitegrast ophthalmic solution) 5% and certain other ophthalmology assets (“Acquisition”) on a Current Report on Form 8-K and on its SEDAR+ (www.sedarplus.ca) profile.

Nektar Therapeutics (Nasdaq: NKTR) today announced that it will host a virtual investor and analyst event on Wednesday, September 13, 2023 at 11:00 a.m. EST / 8:00 a.m. PST to discuss the final Phase 1b data of rezpegaldesleukin (REZPEG) in patients with atopic dermatitis, the atopic dermatitis treatment landscape, and the potential role of REZPEG, Nektar’s novel, first-in-class selective regulatory T-cell (Treg) therapy, in the treatment of atopic dermatitis.